Clinical analysis of bevacizumab targeting therapy in treating early colorectal carcinoma after operation

Li,Tie-Ling; Sun,Zhi-Guo; Jiang,Xiaoming; Guo,Hai-Feng

doi:10.3892/ol.2017.6087

Clinical analysis of bevacizumab targeting therapy in treating early colorectal carcinoma after operation

Authors:
- Tie-Ling Li
- Zhi-Guo Sun
- Xiaoming Jiang
- Hai-Feng Guo
View Affiliations

Affiliations: Pathological Staff Room, Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China, Normal Surgical Department, Hongqi Hospital, Mudanjiang Medical University, Mudanjiang, Heilongjiang 157000, P.R. China, Department of Intensive Care Unit, Hongqi Hospital, Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China
Published online on: April 24, 2017 https://doi.org/10.3892/ol.2017.6087
Pages: 4675-4678
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clinical effects of bevacizumab target therapy in treating early colorectal carcinoma (CRC) after resection were analyzed. Ninety-two patients diagnosed with early CRC and treated with endoscopic mucosal resection for the first time were selected for the study. They were randomly divided into the control group and the observation group with 46 cases in each group. Control group was administered the chemotherapy regimen with oxaliplatin, calcium folinate and 5-fluorouracil, while bevacizumab targeting therapy was given to the observation group. The follow-up median time in these two groups was 30 months. In the observation group, objective response rate and disease control rate were higher than those in the control group, the adverse reaction rate was lower, and the differences were statistically significant (p<0.05). In the observation group, disease-free survival was prolonged (38.6 vs. 30.5 months, p<0.05); the recurrence rate was lower (13.0 vs. 30.4%, p<0.05); the survival rate was improved (91.3 vs. 76.1%, p<0.05). Vascular endothelial growth factor (VEGF) expressions of follow-up serum in these two groups were lower; VEGF expression in the observation group was lower than that in the control group, and the differences had statistical significance (p<0.05). There was no statistical significance in comparison of positive expression in tissue VEGF (p>0.05). In conclusion, after bevacizumab targeting therapy in treating early CRC, VEGF expression of serum was significantly lower; treatment effects improved; adverse drug reaction was reduced; survival time was prolonged; the recurrence rate was reduced; the survival rate improved. It has good application values.

View Figures

View References

1	Yung KW, Yung TT, Chung CY, Tong GT, Liu Y, Henderson J, Welbeck D and Oseni S: Principles of cancer staging. Asian Pac J Surg Oncol. 1:1–16. 2015.
2	Zheng YF, Tan LK, Tan BH, Sterling H and Kane R: Principles of surgical oncology. Asian Pac J Surg Oncol. 1:17–26. 2015.
3	Nasir A, Reising LO, Nedderman DM, Fulford AD, Uhlik MT, Benjamin LE, Schade AE and Holzer TR: Heterogeneity of vascular endothelial growth factor receptors 1, 2, 3 in primary human colorectal carcinoma. Anticancer Res. 36:2683–2696. 2016.PubMed/NCBI
4	Cabart M, Frénel JS, Campion L, Ramée JF, Dupuis O, Senellart H, Hiret S, Douillard JY and Bennouna J: Bevacizumab efficacy is influenced by primary tumor resection in first-line treatment of metastatic colorectal cancer in a retrospective multicenter study. Clin Colorectal Cancer. 7:15–16. 2016.
5	Nagasaka T, Mishima H, Sawaki A, Shimokawa M, Inukai M, Shinozaki K, Tanioka H, Nasu J, Nishina T, Hazama S, et al: Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study. BMJ Open. 6:e0114542016. View Article : Google Scholar : PubMed/NCBI
6	Ocvirk J, Moltara ME, Mesti T, Boc M, Rebersek M, Volk N, Benedik J and Hlebanja Z: Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience. Radiol Oncol. 50:226–231. 2016.PubMed/NCBI
7	Silva GL, de Moura EG, Bernardo WM, de Castro V Leite, Morais C, Baba ER and Safatle-Ribeiro AV: Endoscopic versus surgical resection for early colorectal cancer-a systematic review and meta-analysis. J Gastrointest Oncol. 7:326–335. 2016. View Article : Google Scholar : PubMed/NCBI
8	Probst A and Messmann H: Diagnosis and endoscopic treatment of early colorectal cancer. MMW Fortschr Med. 158:47–49. 2016.(In German). View Article : Google Scholar : PubMed/NCBI
9	Bonetti L Reggiani, Di Gregorio C, de Gaetani C, Pezzi A, Barresi G, Barresi V, Roncucci L and de Leon M Ponz: Lymph node micrometastasis and survival of patients with stage I (Dukes' A) colorectal carcinoma. Scand J Gastroenterol. 46:881–886. 2011. View Article : Google Scholar : PubMed/NCBI
10	Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 15:7412–7420. 2009. View Article : Google Scholar : PubMed/NCBI
11	Verdaguer H, Tabernero J and Macarulla T: Ramucirumab in metastatic colorectal cancer: Evidence to date and place in therapy. Ther Adv Med Oncol. 8:230–242. 2016. View Article : Google Scholar : PubMed/NCBI
12	Gasser M and Waaga-Gasser AM: Therapeutic antibodies in cancer therapy. Adv Exp Med Biol. 917:95–120. 2016. View Article : Google Scholar : PubMed/NCBI
13	Suenaga M, Mashima T, Kawata N, Wakatsuki T, Horiike Y, Matsusaka S, Dan S, Shinozaki E, Seimiya H, Mizunuma N, et al: Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. Oncotarget. 7:34811–34823. 2016.PubMed/NCBI
14	Zong S, Li H, Shi Q, Liu S, Li W and Hou F: Prognostic significance of VEGF-C immunohistochemical expression in colorectal cancer: a meta-analysis. Clin Chim Acta. 458:106–114. 2016. View Article : Google Scholar : PubMed/NCBI
15	Yue GG, Kwok HF, Lee JK, Jiang L, Wong EC, Gao S, Wong HL, Li L, Chan KM, Leung PC, et al: Combined therapy using bevacizumab and turmeric ethanolic extract (with absorbable curcumin) exhibited beneficial efficacy in colon cancer mice. Pharmacol Res. 111:43–57. 2016. View Article : Google Scholar : PubMed/NCBI
16	Michl M, Stintzing S, von Weikersthal L Fischer, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller C, Kahl C, et al: FIRE-3 Study Group: CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). Ann Oncol. 27:1565–1572. 2016. View Article : Google Scholar : PubMed/NCBI
17	Yoshida M, Takagane A, Miyake Y, Shimada K, Nagata N, Sato A, Ogata Y, Fukunaga M, Otsuka K, Takahashi T, et al: A phase II study of third-line combination chemotherapy with bevacizumab plus S-1 for metastatic colorectal cancer with mutated KRAS (SAVIOR Study). Oncology. 91:24–30. 2016. View Article : Google Scholar : PubMed/NCBI